1. What is New in Bladder Cancer Diagnosis and Management?
Jacques Irani, Axel Heidenreich, Nicolas Mottet, Eric Lechevallier 
European Urology Supplements 
Volume 7, Issue 6, Pages (April 2008)
DOI: /j.eursup
Copyright © 2008 European Association of Urology Terms and Conditions

2. Fig. 1
Voting results on the following question: “Which diagnostic marker would you recommend in a systematic fashion in bladder cancer follow-up?”
European Urology Supplements 2008 7, DOI: ( /j.eursup )
Copyright © 2008 European Association of Urology Terms and Conditions

3. Fig. 2
Three-year recurrence-free rates for patients with non–muscle-invasive bladder cancer who received short-term (6 wk) and long-term (3 yr) chemoprophylaxis with mitomycin C (MMC) or short-term (6 wk) immunoprophylaxis with bacillus Calmette-Guérin (BCG) [9].
European Urology Supplements 2008 7, DOI: ( /j.eursup )
Copyright © 2008 European Association of Urology Terms and Conditions